These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26950303)

  • 21. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine.
    Boccadifuoco G; Brunelli B; Mori E; Agnusdei M; Gianfaldoni C; Giuliani MM
    Methods Mol Biol; 2019; 1969():205-215. PubMed ID: 30877679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential impact of the 4CMenB vaccine on oropharyngeal carriage of Neisseria meningitidis.
    Abad R; Medina V; Fariñas MDC; Martínez-Martínez L; Bambini S; Dari A; Medini D; Pizza M; Vázquez JA
    J Infect; 2017 Dec; 75(6):511-520. PubMed ID: 28987549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.
    Parikh SR; Newbold L; Slater S; Stella M; Moschioni M; Lucidarme J; De Paola R; Giuliani M; Serino L; Gray SJ; Clark SA; Findlow J; Pizza M; Ramsay ME; Ladhani SN; Borrow R
    Lancet Infect Dis; 2017 Jul; 17(7):754-762. PubMed ID: 28366725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of invasive
    Sereikaitė E; Plepytė R; Petrutienė A; Stravinskienė D; Kučinskaitė-Kodzė I; Gėgžna V; Ivaškevičienė I; Žvirblienė A; Plečkaitytė M
    Front Cell Infect Microbiol; 2023; 13():1136211. PubMed ID: 36875527
    [No Abstract]   [Full Text] [Related]  

  • 26. Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine.
    Claus H; Jördens MS; Kriz P; Musilek M; Jarva H; Pawlik MC; Meri S; Vogel U
    Vaccine; 2012 Jan; 30(2):155-60. PubMed ID: 22107847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterization of a collection of Neisseria meningitidis isolates from Croatia, June 2009 to January 2014.
    Bukovski S; Vacca P; Anselmo A; Knezovic I; Fazio C; Neri A; Ciammaruconi A; Fortunato A; Palozzi AM; Fillo S; Lista F; Stefanelli P
    J Med Microbiol; 2016 Sep; 65(9):1013-1019. PubMed ID: 27452726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.
    Lucidarme J; Gilchrist S; Newbold LS; Gray SJ; Kaczmarski EB; Richardson L; Bennett JS; Maiden MC; Findlow J; Borrow R
    Clin Vaccine Immunol; 2013 Sep; 20(9):1360-9. PubMed ID: 23803905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
    Vogel U; Taha MK; Vazquez JA; Findlow J; Claus H; Stefanelli P; Caugant DA; Kriz P; Abad R; Bambini S; Carannante A; Deghmane AE; Fazio C; Frosch M; Frosi G; Gilchrist S; Giuliani MM; Hong E; Ledroit M; Lovaglio PG; Lucidarme J; Musilek M; Muzzi A; Oksnes J; Rigat F; Orlandi L; Stella M; Thompson D; Pizza M; Rappuoli R; Serruto D; Comanducci M; Boccadifuoco G; Donnelly JJ; Medini D; Borrow R
    Lancet Infect Dis; 2013 May; 13(5):416-25. PubMed ID: 23414709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China.
    Zhu B; Shi F; Zhang A; Sun X; Xu Z; Xu L; Gao Y; Lv J; Shao Z
    Vaccine; 2018 Apr; 36(15):1983-1989. PubMed ID: 29523451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis.
    Savitskaya VY; Dolinnaya NG; Strekalovskikh VV; Peskovatskova ES; Snyga VG; Trefilov VS; Monakhova MV; Kubareva EA
    Med Sci (Basel); 2023 Dec; 11(4):. PubMed ID: 38132917
    [No Abstract]   [Full Text] [Related]  

  • 35. Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia.
    Mowlaboccus S; Mullally CA; Richmond PC; Howden BP; Stevens K; Speers DJ; Keil AD; Bjørnstad ON; Perkins TT; Kahler CM
    PLoS One; 2017; 12(10):e0186839. PubMed ID: 29065137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic and genotypic characterization of meningococcal isolates in Tunis, Tunisia: High diversity and impact on vaccination strategies.
    Brik A; Terrade A; Hong E; Deghmane A; Taha MK; Bouafsoun A; Khmiri M; Boussetta K; Boukhir S; Jaballah NB; Kechrid A; Smaoui H
    Int J Infect Dis; 2020 Feb; 91():73-78. PubMed ID: 31756567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010-2016.
    Rodrigues CMC; Lucidarme J; Borrow R; Smith A; Cameron JC; Moxon ER; Maiden MCJ
    Emerg Infect Dis; 2018 Apr; 24(4):673-682. PubMed ID: 29553330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.
    Muzzi A; Brozzi A; Serino L; Bodini M; Abad R; Caugant D; Comanducci M; Lemos AP; Gorla MC; Křížová P; Mikula C; Mulhall R; Nissen M; Nohynek H; Simões MJ; Skoczyńska A; Stefanelli P; Taha MK; Toropainen M; Tzanakaki G; Vadivelu-Pechai K; Watson P; Vazquez JA; Rajam G; Rappuoli R; Borrow R; Medini D
    Vaccine; 2019 Feb; 37(7):991-1000. PubMed ID: 30661831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.